GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Cowealth Medical China Co Ltd (SHSE:603122) » Definitions » Growth Rank

Cowealth Medical China Co (SHSE:603122) Growth Rank : 0 (As of Jun. 12, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Cowealth Medical China Co Growth Rank?

Cowealth Medical China Co has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.


Cowealth Medical China Co Growth Rank Related Terms

Thank you for viewing the detailed overview of Cowealth Medical China Co's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Cowealth Medical China Co (SHSE:603122) Business Description

Traded in Other Exchanges
N/A
Address
No. 1001 Qinzhou North Road, 21st Floor, Building 12, Xuhui District, Shanghai, CHN, 200131
Cowealth Medical China Co Ltd operates as a diagnostic clinical laboratory company. It has introduced radiation oncology technology into the market.
Executives
Wang Qiong Zhi Directors, senior managers

Cowealth Medical China Co (SHSE:603122) Headlines

No Headlines